Dr. Carey on Tailoring Treatment in Triple-Negative Breast Cancer

Lisa A. Carey, MD
Published: Monday, Mar 20, 2017



Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Currently, platnium-based treatments are being explored, but they are still a work in progress, says Carey. Studies are showing promise, but there is a lack of information to prove that their success translates into overall survival for patients.

The future of tailoring treatment, says Carey, is based on the effectiveness of biomarker development—including immune biomarkers. Also, non-cytotoxic options need to be included in the treatment landscape, as there are none currently available.
 


Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Currently, platnium-based treatments are being explored, but they are still a work in progress, says Carey. Studies are showing promise, but there is a lack of information to prove that their success translates into overall survival for patients.

The future of tailoring treatment, says Carey, is based on the effectiveness of biomarker development—including immune biomarkers. Also, non-cytotoxic options need to be included in the treatment landscape, as there are none currently available.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x